Structural and functional analysis of the costimulatory receptor programmed death-1.

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Immunity

• Publication date

  2004-03-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/S1074-7613(04)00051-2PMID 15030777
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• CD40/CD40 Homodimers Are Required for CD40-induced Phosphatidylinositol 3-Kinase-dependent Expression of B7.2 by Human B Lymphocytes*

  2004cited by this paper
• Molecular Modeling and Functional Mapping of B7-H1 and B7-DC Uncouple Costimulatory Function from PD-1 Interaction

  2003cited by this paper
• Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade

  2002cited by this paper
• Ligand Binding Sites of Inducible Costimulator and High Avidity Mutants with Improved Function

  2002cited by this paper
• Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion

  2002cited by this paper
• The interaction properties of costimulatory molecules revisited.

  2002cited by this paper
• Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion

  2002cited by this paper
• The B7 family of ligands and its receptors: new pathways for costimulation and inhibition of immune responses.

  2002cited by this paper
• Expression, refolding, purification, molecular characterization, crystallization, and preliminary X-ray analysis of the receptor binding domain of human B7-2.

  2002cited by this paper
• Structural mechanisms of costimulation

  2002cited by this paper
• The B7–CD28 superfamily

  2002cited by this paper
• PD-L2 is a second ligand for PD-1 and inhibits T cell activation

  2001cited by this paper
• Clustering of Peptide-Loaded MHC Class I Molecules for Endoplasmic Reticulum Export Imaged by Fluorescence Resonance Energy Transfer1

  2001cited by this paper
• B7-Dc, a New Dendritic Cell Molecule with Potent Costimulatory Properties for T Cells

  2001cited by this paper
• Crystal structure of the B7-1/CTLA-4 complex that inhibits human immune responses

  2001influential reference
• PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine

  2001cited by this paper
• Structural basis for co-stimulation by the human CTLA-4/B7-2 complex

  2001influential reference
• Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice.

  2001cited by this paper
• Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation

  2000cited by this paper
• Structure of murine CTLA-4 and its role in modulating T cell responsiveness.

  2000cited by this paper
• ESPript: analysis of multiple sequence alignments in PostScript

  1999influential reference
• B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion

  1999influential reference
• Rapid automated molecular replacement by evolutionary search.

  1999influential reference
• Structure of a heterophilic adhesion complex between the human CD2 and CD58 (LFA-3) counterreceptors.

  1999cited by this paper
• Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor.

  1999cited by this paper
• Distribution of a Glycosylphosphatidylinositol-anchored Protein at the Apical Surface of MDCK Cells Examined at a Resolution of <100 Å Using Imaging Fluorescence Resonance Energy Transfer

  1998cited by this paper
• CD2 and the nature of protein interactions mediating cell‐cell recognition

  1998cited by this paper
• Structural specializations of immunoglobulin superfamily members for adhesion to integrins and viruses

  1998cited by this paper
• Crystallography & NMR system: A new software suite for macromolecular structure determination.

  1998influential reference
• Anatomy of hot spots in protein interfaces.

  1998cited by this paper
• Processing of X-ray diffraction data collected in oscillation mode.

  1997cited by this paper
• The human PD-1 gene: complete cDNA, genomic organization, and developmentally regulated expression in B cell progenitors.

  1997cited by this paper
• Solution structure of human CTLA-4 and delineation of a CD80/CD86 binding site conserved in CD28

  1997cited by this paper
• [20] Processing of X-ray diffraction data collected in oscillation mode.

  1997cited by this paper
• Differential effects of CTLA-4 substitutions on the binding of human CD80 (B7-1) and CD86 (B7-2).

  1996cited by this paper
• Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes.

  1996cited by this paper
• SETOR: hardware-lighted three-dimensional solid model representations of macromolecules.

  1993cited by this paper
• Improved methods for building protein models in electron density maps and the location of errors in these models.

  1991cited by this paper
• Protein folding and association: Insights from the interfacial and thermodynamic properties of hydrocarbons

  1991cited by this paper

• T Cell Exhaustion in Cancer Immunotherapy: Heterogeneity, Mechanisms, and Therapeutic Opportunities.

  2026cites this paper
• Recent findings on the PD-1/PD-L1 Axis in breast cancer: Molecular mechanisms, immunotherapeutic potentials, and clinical implications.

  2025cites this paper
• Programmed cell death protein 1 in cancer cells

  2025influential citation
• Risk analysis of cardiovascular toxicity in patients with lymphoma treated with CD19 CAR T cells

  2025cites this paper
• Unmasking a Paradox: Roles of the PD-1/PD-L1 Axis in Alzheimer's Disease-Associated Neuroinflammation

  2025cites this paper
• Fibroblast-like synoviocytes mediate the generation of soluble PD-1 in an MMP-9-dependent manner: a novel target therapy for rheumatoid arthritis

  2025cites this paper
• On the same side: VISTA and its ligands interact in cis on the cell surface

  2025influential citation
• The Molecules with Double-Edged Sword Roles in T Cell: An Implication for Adoptive T Cell Therapy.

  2025cites this paper
• Integrated computational pipeline for advanced sampling-based investigation and alternative inhibition of the programmed cell death protein I pathway

  2025cites this paper
• Immunotropic therapy: blockade of CTLA-4/B7 and PD-1/PD-L1 pathways in the treatment of cancers. Part 1: immunologic aspects

  2025cites this paper
• Immune Checkpoint Molecules: A Review on Pathways and Immunotherapy Implications

  2025cites this paper
• Targeting tumor-draining lymph node to overcome resistance to cancer immunotherapy: an update

  2025cites this paper
• Targeting ligand PDL1 for cardiotoxicity assessment and cardiac protection in immune-related myocarditis.

  2025cites this paper
• A Checkpoint Reversal Receptor Mediates Bipartite Activation and Enhances CAR T-cell Function

  2025cites this paper
• The interaction of PD-1/PD-L1 and its inhibition by anti-PD-L1 antibody at the single-molecule level.

  2025cites this paper
• Modulation of N-glycosylation in the PD-1: PD-L1 axis as a strategy to enhance cancer immunotherapies.

  2025cites this paper
• Drug Treatment Direction Based on the Molecular Mechanism of Breast Cancer Brain Metastasis

  2025cites this paper
• Oncolytic Viruses Reshape PD‐1/PD‐L1 Signaling: Mechanisms and Clinical Synergy With Immune Checkpoint Blockade

  2025cites this paper
• Emerging roles of checkpoint molecules on B cells

  2025cites this paper
• Preclinical models of immune checkpoint inhibitors-related interstitial pneumonia for anti-PD1 tumor immunotherapy.

  2025cites this paper
• Immune Checkpoint Inhibitors (ICI) in Urological Cancers: A New Modern Era, but Not Generally Applied

  2025cites this paper
• Modified epitope peptides targeting the porcine PD-1/PD-L1 interaction enhance cellular and humoral immune responses

  2025cites this paper
• Ferroptosis meets cancer immunotherapy: Overcoming the crosstalk challenges through advanced drug delivery strategies

  2025cites this paper
• Upregulation of PD-1 on Peripheral T cells Subsets is Associated with Parkinson's Disease

  2025cites this paper
• Negative Immune Checkpoint Inhibitors

  2025cites this paper
• Molecular characterisation of lupus low disease activity state (LLDAS) and DORIS remission by whole-blood transcriptome-based pathways in a pan-European systemic lupus erythematosus cohort

  2024cites this paper
• The role of PD-1/PD-L1 signaling pathway in cancer pathogenesis and treatment: a systematic review

  2024cites this paper
• Risk factors for immune-related adverse effects during CPI therapy in patients with head and neck malignancies – a single center study

  2024cites this paper
• Transmembrane domain–driven PD-1 dimers mediate T cell inhibition

  2024cites this paper
• Molecular Subtypes, microRNAs and Immunotherapy Response in Metastatic Colorectal Cancer

  2024cites this paper
• Anti-Tumor Potential of Post-Translational Modifications of PD-1

  2024cites this paper
• Soluble immune checkpoints: implications for cancer prognosis and response to immune checkpoint therapy and conventional therapies

  2024cites this paper
• Beyond peptides: Unveiling the design strategies, structure activity correlations and protein-ligand interactions of small molecule inhibitors against PD-1/PD-L1.

  2024cites this paper
• Pembrolizumab for metastatic castration-resistant prostate cancer: trials and tribulations

  2024cites this paper
• Molecular Imaging of PD-1 Unveils Unknown Characteristics of PD-1 Itself by Visualizing "PD-1 Microclusters".

  2024cites this paper
• Insights into the molecular mechanisms of H. pylori-associated B-cell lymphoma

  2024cites this paper
• Predictive Biomarkers and Resistance Mechanisms of Checkpoint Inhibitors in Malignant Solid Tumors

  2024cites this paper
• Role of PD-1/PD-L1 crosstalk on inhibition of T-cell activation and proliferation through blockade of PI3K/Akt/mTOR signaling pathway

  2024cites this paper
• A comprehensive review of immune checkpoint inhibitors for cancer treatment.

  2024cites this paper
• A future directions of renal cell carcinoma treatment: combination of immune checkpoint inhibition and carbon ion radiotherapy

  2024cites this paper
• Current Trends and Innovative Approaches in Cancer Immunotherapy

  2024cites this paper
• Exploring the mediating role of immune cells in the pathogenesis of IgA nephropathy through the inflammatory axis of gut microbiota from a genomic perspective

  2024cites this paper
• On the same side: The immune regulatory protein Vista and its ligands interact in cis

  2024cites this paper
• Immunoinformatics approach: Developing a multi‐epitope vaccine with novel carriers targeting monkeypox virus

  2024cites this paper
• Construction of Switch Modules for CAR-T Cell Treatment Using a Site-Specific Conjugation System.

  2024cites this paper
• Engineering PD-1-targeted small protein variants for in vitro diagnostics and in vivo PET imaging

  2024cites this paper
• Immune checkpoint activity exacerbate renal interstitial fibrosis progression by enhancing PD-L1 expression in renal tubular epithelial cells.

  2024cites this paper
• Hsa_circ_0004872 mitigates proliferation, metastasis and immune escape of meningioma cells by suppressing PD-L1

  2024cites this paper
• The synergistic immunotherapeutic impact of engineered CAR-T cells with PD-1 blockade in lymphomas and solid tumors: a systematic review

  2024cites this paper
• Exosomal PD-L1 in cancer and other fields: recent advances and perspectives

  2024cites this paper
• Emerging therapeutic frontiers in cancer: insights into posttranslational modifications of PD-1/PD-L1 and regulatory pathways

  2024cites this paper
• Doxorubicin induces deglycosylation of cancer cell‐intrinsic PD‐1 by NGLY1

  2024cites this paper
• TEDOVA: vaccine OSE2101 +/- pembrolizumab as maintenance in platinum-sensitive recurrent ovarian cancer

  2024cites this paper
• Regulatory mechanisms of PD-1/PD-L1 in cancers

  2024cites this paper
• The tumor suppressor effect of miRNA 200-c-3p on A549 non-small cell lung cancer cell line is associated with down-regulation of programmed cell death ligand 1; an immune-check point mechanism.

  2024cites this paper
• A Systematic Review of the Advances in the Study of T Lymphocyte Suppressor Receptors in HBV Infection: Potential Therapeutic Targets

  2024cites this paper
• PD-1 expression in transbronchial biopsies of lung transplant recipients is a possible early predictor of rejection

  2023cites this paper
• Research Progress of Immune Checkpoint Inhibitors in Melanoma

  2023cites this paper
• The emerging roles of PD-L1 subcellular localization in tumor immune evasion.

  2023cites this paper
• PD-1: A new candidate target for analgesic peptide design.

  2023cites this paper
• The role of immune checkpoints in antitumor response: a potential antitumor immunotherapy

  2023cites this paper
• PD-1 receptor outside the main paradigm: tumour-intrinsic role and clinical implications for checkpoint blockade

  2023cites this paper
• The immune checkpoint protein PD-1: Its emerging regulatory role in memory T cells.

  2023cites this paper
• New insights into T-cell exhaustion in liver cancer: from mechanism to therapy

  2023cites this paper
• Immune checkpoint therapy for solid tumours: clinical dilemmas and future trends

  2023cites this paper
• Detailed characterization of PD-1/PD-L1 and CTLA4 expression and tumor-infiltrating lymphocytes in yolk sac tumors.

  2023cites this paper
• Development of PD-1 blockade peptide-cell conjugates to enhance cellular therapies for T-cell acute lymphoblastic leukemia

  2023influential citation
• Charting new frontiers: Co-inhibitory immune checkpoint proteins in therapeutics, biomarkers, and drug delivery systems in cancer care

  2023cites this paper
• Inside PD-1/PD-L1,2 with their inhibitors.

  2023cites this paper
• Posttransplant cyclophosphamide contributes to the impairment of the graft-versus-leukemia effect and the amelioration of graft-versus-host disease with the suppression of alloreactive T cells in a murine stem cell transplant model.

  2023cites this paper
• PD-1/PD-L1 axis in organ fibrosis

  2023cites this paper
• Triptolide reduces PD-L1 through the EGFR and IFN-γ/IRF1 dual signaling pathways.

  2023cites this paper
• SnoRNA and lncSNHG: Advances of nucleolar small RNA host gene transcripts in anti-tumor immunity

  2023cites this paper
• Immunotherapies in chronic pain through modulation of neuroimmune interactions.

  2023cites this paper
• Characteristics and postoperative dynamic changes in circulating CD4+ helper T lymphocytes in patients with breast cancer

  2023cites this paper
• The impact of hypoxia on tumor-mediated bypassing anti-PD-(L)1 therapy.

  2023cites this paper
• Targeting RNA N6-methyladenosine to synergize with immune checkpoint therapy

  2023cites this paper
• Predicting a Stable Dimeric Form of the PD1-PDL1 Complex: Implications for Understanding the PD1 Activation Mechanism.

  2023cites this paper
• The role of LncRNAs in tumor immunotherapy

  2023cites this paper
• Clinical outcome and biomarker assessments of a multi-centre phase II trial assessing niraparib with or without dostarlimab in recurrent endometrial carcinoma

  2023cites this paper
• Analysis of Immune Resistance Mechanisms in TNBC: Dual Effects Inside and Outside the Tumor.

  2023cites this paper
• Research progress of therapeutic effects and drug resistance of immunotherapy based on PD-1/PD-L1 blockade.

  2022cites this paper
• Programmed Cell Death-Ligand 1 in Head and Neck Squamous Cell Carcinoma: Molecular Insights, Preclinical and Clinical Data, and Therapies

  2022cites this paper
• The impact of microbiota on PD-1/PD-L1 inhibitor therapy outcomes: A focus on solid tumors.

  2022cites this paper
• Myasthenia gravis during treatment with anti-PD-1 - succesfull treatment using pirydostygminum – case report and literature review

  2022cites this paper
• Focus on PD-1/PD-L1 as a Therapeutic Target in Ovarian Cancer

  2022cites this paper
• Immune checkpoint inhibitors in osteosarcoma: A hopeful and challenging future

  2022cites this paper
• Quantification of promoting efficiency and reducing toxicity of Traditional Chinese Medicine: A case study of the combination of Tripterygium wilfordii hook. f. and Lysimachia christinae hance in the treatment of lung cancer

  2022cites this paper
• Assessment of Soluble PD-1 and PD-L1 in Iraqi Women Patients with Breast Cancer with Toxoplasmosis

  2022cites this paper
• Identification, binding, and structural characterization of single domain anti-PD-L1 antibodies inhibitory of immune regulatory proteins PD-1 and CD80

  2022cites this paper
• Novel targets for immunotherapy associated with exhausted CD8 + T cells in cancer

  2022cites this paper
• New advances in pharmaceutical strategies for sensitizing anti-PD-1 immunotherapy and clinical research.

  2022cites this paper
• The role of immune regulatory molecules in rheumatoid arthritis: Implication for etiopathogenesis and prospective for treatment

  2022cites this paper
• TNF-α inhibitor ameliorates immune-related arthritis and pneumonitis in humanized mice

  2022cites this paper
• An affinity threshold for maximum efficacy in anti-PD-1 immunotherapy

  2022cites this paper
• Natural Products and their Derivatives as Immune Check Point Inhibitors: Targeting Cytokine/Chemokine Signalling in Cancer.

  2022cites this paper
• Prediction of Immune-Related Adverse Events Induced by Immune Checkpoint Inhibitors With a Panel of Autoantibodies: Protocol of a Multicenter, Prospective, Observational Cohort Study

  2022cites this paper
• Regulatory T cells-centered regulatory networks of skeletal muscle inflammation and regeneration

  2022cites this paper
• New insights into checkpoint inhibitor immunotherapy and its combined therapies in hepatocellular carcinoma: from mechanisms to clinical trials

  2022cites this paper
• CMAR_A_351383 1267..1281

  2022cites this paper